Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

AA data by YCharts

Image placeholder title

Alcoa (AA) - Get Report : In an exclusive interview, Cramer kicked off earnings season by speaking with Klaus Kleinfeld, chairman and CEO of Alcoa, the aluminum producer splitting itself in two to create a commodity producer and an high-tech aluminum solutions provider.

Kleinfeld said there's been lots of volatility in the aluminum market, but Alcoa remains well positioned in all of the high growth markets including transportation, construction and aerospace. If all of those areas, he added, Alcoa is growing faster than the market.

When asked about demand for aluminum, Kleinfeld explained production cuts around the globe are working and global demand is expected to increase by 6%, meaning there will be a deficit of aluminum, which will stabilize pricing.

On the value-added side of the business, Kleinfeld said there is no shortage of innovation. Thanks to many smart acquisitions, areas like jet engines continues to see lots of innovation, as do titanium products.

With share prices stagnant, Cramer said Alcoa remains a buy.

HZNP data by YCharts

Image placeholder title

Horizon Pharmaceuticals (HZNP) - Get Report : In his second exclusive interview, Cramer also checked in with Tim Walbert, chairman, president and CEO at Horizon, the orphan drugmaker that closed down 4.7% today and is off 50% from its high last year.

Walbert addressed concerns about drug pricing by explaining the list price on the company's drugs helps subsidize those patients in need, and most patients pay only $10 for Horizon products as a result. He added the strong cash flows generated by Horizon's existing drugs is helping to fund its expansion into the orphan drug space.

When asked about those orphan drugs, Walbert said the market for bladder cancer, for example, is estimated to be between $300 million and $500 million for Horizon by 2020.

Cramer said with the drug stocks under so much pressure, perhaps these stocks have been beaten up enough.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.